概述
Drug safety is a broad topic. Certara’s in silico toxicology software enables pharmaceutical, biotech, chemical, and agrochemical companies to predict toxicological outcomes, assess compound safety, and generate regulatory-ready reports on an easy-to-use interface.
The FDA’s Roadmap to reducing animal testing in preclinical studies (April, 2025) sets out an ambitious and clear objective “to make animal studies the exception rather than the norm for preclinical safety/toxicity testing” within 3-5 years from now.
In this webinar, we introduce ToxStudio®, a suite of in silico tools addressing preclinical safety challenges:
- Libra™ – AI-powered DILI prediction
- Cardiac Safety Simulator™ – Modeling and simulation platform to predict QT/proarrhythmia risk
- Secondary Intelligence™ – Secondary pharmacology software to contextualize and categorize off-target risks
Key Learning Objectives:
- Understand the FDA’s New Approach Methdology (NAMs) Roadmap
- Learn where to start with in silico NAMs for the safety and toxicology assessment
点击报名
Vice President, Quantitative Systems Toxicology and Safety, Certara
Will 带领 QSTS 团队应用计算方法来评估药物和其他化学品的安全性。他是一位经验丰富的安全药理学家，曾在 Syntex、Quintiles 和 AstraZeneca 任职。他是安全性药理学协会的前任主席。
点击报名
